Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma

Traditionally, overall survival (os) has been considered the “gold standard” for evaluating new systemic oncologic therapies, because death is easy to define, is easily compared across disease sites, and is not subject to investigator bias. However, as the available options for continuing therapy in...

Full description

Saved in:
Bibliographic Details
Main Authors: Hotte, S.J., Bjarnason, G.A., Heng, D.Y.C., Jewett, M.A.S., Kapoor, A., Kollmannsberger, C., Maroun, J., Mayhew, L.A., North, S., Reaume, M.N., Ruether, J.D., Soulieres, D., Venner, P.M., Winquist, E.W., Wood, L., Yong, J.H.E., Saad, F.
Format: Artigo
Language:Inglês
Published: Multimed Inc. 2011
Subjects:
Medical Oncology
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3176905/
https://ncbi.nlm.nih.gov/pubmed/21969807
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items